News ArticleMetropolis Healthcare Posts INR 1,193.34 Million Profit for H1 FY2026-27 and Declares INR 1 Interim Dividend per Share
Company announces unaudited results for Q2 and H1 ending September 30, 2026, with dividend record date set for November 9, 2026
Metropolis Healthcare Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company reported a profit for the half year of INR 1,193.34 million and declared an interim dividend of INR 1 per equity share for FY 2026-27, payable to shareholders on record as of November 09, 2026.
Metropolis Healthcare Limited
Financial Results
Metropolis Healthcare Limited released its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, reporting a profit after tax of INR 1,193.34 million for the half year period. The company also declared an interim dividend of INR 1 per equity share with a record date of November 9, 2026.
The company’s total income for the six months ending September 30, 2026, reached INR 8,033.92 million, compared to INR 6,840.25 million during the corresponding period in the previous year.
Total expenses for the half year were INR 6,431.62 million, resulting in a profit before tax of INR 1,602.30 million.
The profit for continuing operations after tax was INR 1,194.05 million for the half year, contributing the majority of total profit.
An interim dividend of INR 1 per equity share (face value INR 2 each) has been declared for the financial year 2026-27, with a payment record date of November 9, 2026.
The financial results have undergone limited review by Deloitte Haskins & Sells LLP, with no modifications or qualifications noted in the report.
Highlights
- Total income for H1 FY2026-27: INR 8,033.92 million
- Profit for the half year ended September 30, 2026: INR 1,193.34 million
- Interim dividend declared at INR 1 per equity share (face value INR 2)
- Dividend record date set for November 9, 2026
- Limited review report issued by Statutory Auditors with no qualifications
Key Data Snapshot
What happened
- Metropolis Healthcare approved its unaudited standalone and consolidated financial results for Q2 and H1 FY2026-27.
- The company declared an interim dividend of INR 1 per equity share of face value INR 2 each for the financial year 2026-27.
- The dividend record date was set for November 09, 2026, with payment to be made within 30 days of declaration.
Financial performance
- Total income for the half year ended September 30, 2026, was INR 8,033.92 million, up from INR 6,840.25 million in the previous year.
- Profit after tax for continuing operations was INR 1,194.05 million during the six months period.
- Total expenses during this period amounted to INR 6,431.62 million.
- Earnings per share (basic) for the six months period stood at INR 5.76.
Regulatory and governance context
- Financial results and limited review report were reviewed by Deloitte Haskins & Sells LLP, with an unmodified conclusion.
- Results were approved by the company's Board of Directors on November 3, 2026.
- The disclosures comply with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Highlights
- Total income for H1 FY2026-27: INR 8,033.92 million
- Profit for the half year ended September 30, 2026: INR 1,193.34 million
- Interim dividend declared at INR 1 per equity share (face value INR 2)
- Dividend record date set for November 9, 2026
- Limited review report issued by Statutory Auditors with no qualifications
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Source Information
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Biocon Limited Reports Rs. 1,439 Million Profit for H1 FY2026-27; Appoints Mukesh Rathi as New CTO from January 2027
Biocon Limited declared its unaudited standalone financial results for the quarter and half-year ended September 30, 2026, reporting a profit of Rs. 1,439 million for the half-year. Alongside financial disclosure, the company announced a change in its senior management with the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as the new CTO starting January 1, 2027.
Read Full Story
Zydus Lifesciences Posts ₹10,541 Million Net Profit for Half Year Ending September 30, 2026
Zydus Lifesciences Limited announced its unaudited standalone financial results for the quarter and half year ended September 30, 2026, recording a net profit of ₹7,145 million for Q2 and ₹10,541 million for the half year.
Read Full Story
Fractal Analytics Limited Reports Unaudited Q2 and H1 2026 Financial Results and Approves Winding Up of Analytics Vidhya Inc
Fractal Analytics Limited announced its unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2026. Additionally, the company's Board has approved winding up its step-down subsidiary Analytics Vidhya Inc., aiming to simplify group corporate structure and enhance operational efficiency without affecting ongoing business activities.
Read Full Story
